Incretin Mimetics Drugs Market
- 2026 年市場規模
- USD 59,883.0 Mn
- 2033 年預估規模
- USD 102,444.8 Mn
- 年複合成長率 CAGR
- 11.6%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Incretin Mimetics Drugs Market, By Brand (Ozempic (semaglutide), Trulicity Pen (dulaglutide), Wegovy (semaglutide), Saxenda (Liraglutide), Victoza (Liraglutide), Rybelsus (semaglutide), Zepbound (Tirzepatide), Mounjaro (Tirzepatide), BYDUREON Bcise (exenatide), and Others (Januvia and Janumet, etc.) (Sitagliptin)), By Drug (Semaglutide, Tirzepatide, Dulaglutide, Exenatide, Liraglutide, and Others), By Route of Administration (Subcutaneous and Oral), By Type (Branded and Generic), By Age Group (Pediatric/Children and Adult), By Gender (Male and Female), By Indication (Type 2 Diabetes Mellitus (T2DM), Weight Management(Obesity/Overweight), Cardiovascular Risk Reduction, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
報告摘要
The global incretin mimetics drugs market is estimated to be valued at USD 59,883.0 Mn in 2026 and is expected to reach USD 102,444.8 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 11.6% from 2026 to 2033. The global incretin mimetics drugs market represents a rapidly evolving segment within the pharmaceutical industry, focusing on innovative therapeutic solutions for diabetes management and related metabolic disorders.
Incretin mimetics, also known as GLP-1 receptor agonists and DPP-4 inhibitors, are a class of antidiabetic medications that mimic the action of incretin hormones naturally produced in the intestine. These drugs work by stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and promoting satiety, thereby providing comprehensive glycemic control. The market encompasses various drug formulations including injectable and oral medications, with leading pharmaceutical companies investing heavily in research and development to enhance efficacy and patient compliance.
The therapeutic landscape has witnessed significant advancement with the introduction of long-acting formulations, combination therapies, and expanded indications beyond diabetes management, including cardiovascular protection and weight management. As healthcare systems worldwide grapple with the rising prevalence of type 2 diabetes and obesity, incretin mimetics have emerged as cornerstone treatments offering superior clinical outcomes compared to traditional antidiabetic agents. The market's growth trajectory is supported by increasing disease burden, growing awareness about diabetes complications, technological advancements in drug delivery systems, and expanding healthcare infrastructure in emerging economies.
Market Dynamics
The global incretin mimetics drugs market is primarily driven by the escalating prevalence of type 2 diabetes mellitus worldwide, with the International Diabetes Federation estimating over 537 million adults living with diabetes globally, creating substantial demand for effective therapeutic interventions. The superior efficacy profile of incretin mimetics, including their ability to provide sustained glycemic control with minimal hypoglycemic risk and additional benefits such as weight reduction and cardiovascular protection, has positioned these drugs as preferred treatment options among healthcare providers. Growing geriatric population, sedentary lifestyles, rising obesity rates, and increasing healthcare expenditure further propel market expansion.
Additionally, continuous innovation in drug formulations, including once-weekly injectable options and oral alternatives, enhances patient adherence and treatment outcomes. However, the market faces significant restraints including high treatment costs compared to conventional antidiabetic medications, limiting accessibility particularly in price-sensitive markets and developing regions. Patent expirations of blockbuster drugs and subsequent biosimilar competition pose pricing pressures on manufacturers. Potential side effects such as gastrointestinal disturbances, pancreatitis risks, and rare cases of thyroid tumors in preclinical studies create prescriber hesitancy and regulatory scrutiny.
Nevertheless, substantial opportunities exist through expanding indications beyond diabetes, including obesity management and potential applications in neurodegenerative diseases. Emerging markets in Asia Pacific, Latin America, and Africa present untapped potential due to improving healthcare infrastructure and rising diabetes awareness. The development of combination therapies, personalized medicine approaches, and digital health integration offer additional growth avenues for market participants.
Key Features of the Study
• This report provides in-depth analysis of the global incretin mimetics drugs market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global incretin mimetics drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novo Nordisk, Eli Lilly and Company, AstraZeneca, Sanofi, Boehringer Ingelheim, Amgen, Roche, Genentech, Zealand Pharma, Pfizer, Viking Therapeutics, Structure Therapeutics, Innovent Biologics, Hanmi Pharmaceutical, and Eccogene
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global incretin mimetics drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global incretin mimetics drugs market
Market Segmentation
• Brand Insights (Revenue, USD Mn, 2021 - 2033)
o Ozempic (semaglutide)
o Trulicity Pen (dulaglutide)
o Wegovy (semaglutide)
o Saxenda (Liraglutide)
o Victoza (Liraglutide)
o Rybelsus (semaglutide)
o Zepbound (Tirzepatide)
o Mounjaro (Tirzepatide)
o BYDUREON Bcise (exenatide)
o Others (Januvia and Janumet, etc.) (Sitagliptin)
• Drug Insights (Revenue, USD Mn, 2021 - 2033)
o Semaglutide
o Tirzepatide
o Dulaglutide
o Exenatide
o Liraglutide
o Others
• Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
o Subcutaneous
o Oral
• Type Insights (Revenue, USD Mn, 2021 - 2033)
o Branded
o Generic
• Age Group Insights (Revenue, USD Mn, 2021 - 2033)
o Pediatric/Children
o Adult
• Gender Insights (Revenue, USD Mn, 2021 - 2033)
o Male
o Female
• Indication Insights (Revenue, USD Mn, 2021 - 2033)
o Type 2 Diabetes Mellitus (T2DM)
o Weight Management (Obesity/Overweight)
o Cardiovascular Risk Reduction
o Others
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o Novo Nordisk
o Eli Lilly and Company
o AstraZeneca
o Sanofi
o Boehringer Ingelheim
o Amgen
o Roche
o Genentech
o Zealand Pharma
o Pfizer
o Viking Therapeutics
o Structure Therapeutics
o Innovent Biologics
o Hanmi Pharmaceutical
o Eccogene
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Global Incretin Mimetics Drugs Market, By Brand
Global Incretin Mimetics Drugs Market, By Drug
Global Incretin Mimetics Drugs Market, By Route of Administration
Global Incretin Mimetics Drugs Market, By Type
Global Incretin Mimetics Drugs Market, By Age Group
Global Incretin Mimetics Drugs Market, By Gender
Global Incretin Mimetics Drugs Market, By Indication
Global Incretin Mimetics Drugs Market, By Distribution Channel
Global Incretin Mimetics Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Key Developments
o Industry Trends
4. Global Incretin Mimetics Drugs Market, By Brand, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Ozempic (semaglutide)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Trulicity Pen (dulaglutide)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Wegovy (semaglutide)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Saxenda (Liraglutide)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Victoza (Liraglutide)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Rybelsus (semaglutide)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Zepbound (Tirzepatide)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Mounjaro (Tirzepatide)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o BYDUREON Bcise (exenatide)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others (Januvia and Janumet, etc.) (Sitagliptin)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Incretin Mimetics Drugs Market, By Drug, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Semaglutide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Tirzepatide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Dulaglutide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Exenatide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Liraglutide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Incretin Mimetics Drugs Market, By Route of Administration, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Subcutaneous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Incretin Mimetics Drugs Market, By Type, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Branded
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Generic
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Incretin Mimetics Drugs Market, By Age Group, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Pediatric/Children
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Adult
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
9. Global Incretin Mimetics Drugs Market, By Gender, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Male
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Female
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
10. Global Incretin Mimetics Drugs Market, By Indication, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Type 2 Diabetes Mellitus (T2DM)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Weight Management (Obesity/Overweight)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Cardiovascular Risk Reduction
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
11. Global Incretin Mimetics Drugs Market, By Distribution Channel, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
12. Global Incretin Mimetics Drugs Market, By Region, 2021 - 2033, Value (USD Mn)
o Introduction
Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
Regional Trends
o North America
Introduction
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o Germany
o U.K.
o Spain
o France
o Italy
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
o South Africa
o North Africa
o Central Africa
13. Competitive Landscape
o Novo Nordisk
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o AstraZeneca
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Sanofi
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Boehringer Ingelheim
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Amgen
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Roche
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Genentech
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Zealand Pharma
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Pfizer
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Viking Therapeutics
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Structure Therapeutics
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Innovent Biologics
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Hanmi Pharmaceutical
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Eccogene
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
14. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
15. References and Research Methodology
o References
o Research Methodology
o About us
*Browse 32 market data tables and 28 figures on 'Incretin Mimetics Drugs Market' - Global forecast to 2033
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們